DISCOVER FINANCE

On October 22, pharmaceutical giant, Gilead Sciences, acquired PepStar Therapeutics’ oral inflammation drug program in a deal worth $1.275 billion in upfront cash. A primary drug involved in the agreement is HCXT-2001, an experimental treatment that is currently undergoing Phase 1 clinical trials. This acquisition marks another step in Gilead’s expansion beyond its core HIV business. HCXT-2001 targets the interleukin-23 (IL-23) receptor, which regulates immune responses asso

On October 28, 2026, Google parent Alphabet saw its shares plunge after the release of their third quarter earnings report. Investor concerns centered around rising artificial intelligence expenses and underwhelming advertising revenue. Alphabet’s mounting infrastructure costs have raised questions about the profitability of AI investments. Alphabet reported quarterly revenue of $127.6 billion, a 25% increase year over year but below Wall Street's expectation of $128.2 billi

Merck's (NYSE: MRK) new cancer treatment, sacituzumab tirumotecan (sac-TMT), showed improved survival in patients with advanced or recurrent endometrial cancer. This was unveiled on October 26 and could help Merck secure its place in a rapidly expanding market for targeted cancer therapies. The Phase 3 trial saw patients receiving sac-TMT achieve a median overall survival of 19 months, compared to just 12.1 months in those receiving traditional chemotherapy. This represented

London Stock Exchange Group (LSE: LSEG) is set to acquire a financial data provider called Octus in a $3.54 billion deal, representing the biggest acquisition by the group in seven years. The move follows fears that artificial intelligence will disrupt the financial information sector in favor of more innovative firms. On the news, the provider of financial data and analytics saw its shares jump by around 6%, thereby erasing its losses for the year. Octus, based in New York,

Moderna is best known for its breakthrough COVID-19 vaccines back during the pandemic. However, the company now focuses on developing cancer treatments and is approaching a critical milestone. On October 24, 2026, Moderna and its partner Merck are set to present their phase 3 results for intismeran autogene, an advanced personalized mRNA vaccine for battling cancer. After positive trial results earlier in August, Moderna shares have already jumped 284%, meaning that this upco

Confidence in Intel seems to be rising again as shares climbed 2.4% on October 19, 2026. This is likely attributed to JPMorgan’s upgrade of the company from Underweight to Neutral. The rebound is especially significant as it follows a rather rough week for the semiconductor giant, where shares plummeted more than 14%, wiping out approximately $78.5 billion in market capitalization. Despite the recent sell-off, Intel’s small recovery signals increasing recognition of the compa